{
  "ticker": "JNJ",
  "date": "2023-03-13",
  "lookback_days": 14,
  "fetched_at": "2026-02-13T11:50:33.100179",
  "source": "alpha_vantage",
  "article_count": 5,
  "articles": [
    {
      "title": "J&J-backed startup launches with $100M to build better brain drugs",
      "summary": "Rapport Therapeutics, a neuroscience-focused biotech, has launched with $100 million in Series A funding from venture capital firms and Johnson & Johnson's innovation arm. The company aims to develop more precise treatments for neurological disorders by targeting receptor-associated proteins (RAPs) that are localized to specific brain regions. Its most advanced program is already in early human testing for drug-resistant seizure disorders",
      "url": "https://www.biopharmadive.com/news/rapport-therapeutics-launch-series-a-johnson-johnson/644298/",
      "source": "BioPharma Dive",
      "published": "20230307T153026",
      "overall_sentiment_score": 0.16671,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.346699,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.815771
    },
    {
      "title": "Rapport Therapeutics Snags $100M for Precision Approach to Neurological Diseases",
      "summary": "Rapport Therapeutics, a clinical-stage biotech focused on precision medicines for neurological disorders, has raised $100 million in Series A financing from Third Rock Ventures, ARCH Venture Partners, and Johnson & Johnson Innovation. The company's platform uses small-molecule drugs to target receptor-associated proteins (RAPs) in specific neuroanatomical regions, aiming for higher efficacy and better-tolerated treatments. Rapport's lead program is currently in Phase I for drug-resistant seizure disorders, with CEO Abe Ceesay emphasizing the platform's potential to address unmet needs with highly specific therapies.",
      "url": "https://www.biospace.com/rapport-therapeutics-launches-with-100m-for-novel-neurological-approach",
      "source": "BioSpace",
      "published": "20230307T153026",
      "overall_sentiment_score": 0.17145,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.30403,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.74048
    },
    {
      "title": "Rapport Therapeutics Launches with $100 Million to Transform the Treatment of Neurological Disease through the Discovery and Development of Precision Therapies",
      "summary": "Rapport Therapeutics has launched with $100 million in Series A financing to develop precision medicines for neurological disorders. The company's novel platform targets specific neural circuits using receptor-associated proteins, with its lead asset already in Phase 1 for seizure disorders. Abraham Ceesay has been appointed as CEO to lead the company's mission to transform neuroscience treatment.",
      "url": "https://www.businesswire.com/news/home/20230307005230/en/Rapport-Therapeutics-Launches-with-%24100-Million-to-Transform-the-Treatment-of-Neurological-Disease-through-the-Discovery-and-Development-of-Precision-Therapies",
      "source": "Business Wire",
      "published": "20230307T153026",
      "overall_sentiment_score": 0.246812,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.415841,
      "ticker_sentiment_label": "Bullish",
      "relevance_score": 0.71031
    },
    {
      "title": "Schwab U.S. Large-Cap Value ETF Holdings List (NYSEARCA:SCHV)",
      "summary": "This article provides a list of the top 25 holdings of the Schwab U.S. Large-Cap Value ETF (NYSEARCA: SCHV). The ETF's holdings include major companies like Berkshire Hathaway, JPMorgan Chase & Co., and Exxon Mobil, detailing their current price, weight within the ETF, and shares held. The data reflects the closing prices as of January 2, 2026.",
      "url": "https://www.marketbeat.com/stocks/NYSEARCA/SCHV/holdings/",
      "source": "MarketBeat",
      "published": "20230228T130905",
      "overall_sentiment_score": 0.159218,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.094474,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.610015
    },
    {
      "title": "CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies",
      "summary": "CARGO Therapeutics has successfully raised $200 million in an oversubscribed and upsized Series A financing round. This funding will be used to advance their pipeline of next-generation CAR T-cell therapies, including their lead candidate CRG-022 (CD22 CAR) for large B-cell lymphoma (LBCL) patients who have relapsed after CD19 CAR T-cell therapy. The company plans to commence a pivotal Phase 2 trial for CRG-022 in mid-2023, building on promising initial Phase 1 results and a Breakthrough Therapy Designation from the FDA.",
      "url": "https://www.globenewswire.com/news-release/2023/03/01/2618358/0/en/CARGO-Therapeutics-Raises-200-Million-in-Oversubscribed-Upsized-Series-A-Financing-to-Advance-its-Pipeline-of-Next-Generation-CAR-T-Cell-Therapies.html",
      "source": "GlobeNewswire",
      "published": "20230301T093000",
      "overall_sentiment_score": 0.131095,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment_score": 0.137697,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.595858
    }
  ]
}